69
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Molecular evidence of a genotypically novel large T-cell lymphoma after anti-CD4 therapy for refractory mycosis fungoides

, &
Pages 905-907 | Received 16 Oct 2010, Accepted 20 Dec 2010, Published online: 08 Feb 2011

References

  • Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkin's lymphoma. Neth J Med 2009;67: 311–321.
  • Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109:4655–4662.
  • Faguer S, Launay F, Ysebaert L, et al. Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab. Br J Dermatol 2007;157:841–842.
  • Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988;132:265–277.
  • Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000;95:2212–2218.
  • Barberio E, Thomas L, Skowron F, Balme B, Dalle S. Transformed mycosis fungoides: clinicopathological features and outcome. Br J Dermatol 2007;157:284–289.
  • Prochazkova M, Chevret E, Beylot-Barry M, et al. Large cell transformation of mycosis fungoides: tetraploidization within skin tumor large cells. Cancer Genet Cytogenet 2005;163:1–6.
  • Ponti R, Fierro MT, Quaglino P, et al. TCRgamma-chain gene rearrangement by PCR-based GeneScan: diagnostic accuracy improvement and clonal heterogeneity analysis in multiple cutaneous T-cell lymphoma samples. J Invest Dermatol 2008;128:1030–1038.
  • Villadsen LS, Skov L, Dam TN, et al. In situ depletion of CD4+ T cells in human skin by zanolimumab. Arch Dermatol Res 2007;298:449–455.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.